PHARMACY

Biogden Idec full-year and Q4 2007 results note success

BY Diana Alickaj

CAMBRIDGE, Mass. Biogden Idec increased total revenue by 18 percent, a total of $3.17 billion—from the $2.86 billion in the year 2006. Biogden Idec is a global biotechnology company that deals with the development, manufacturing and commercialization of innovative therapies.

Fourth-quarter revenue for the company increased 26 percent with a total of $893 million from its $708 million total in 2006. The company’s long-term business plan included a total revenue growth of 15 percent to 18 percent over 2007, increasing operating leverage, and a Non-GAAP tax rate expected to be 28 percent to 30 percent.

“We’re extremely proud of our accomplishments in 2007. We grew revenues by 18 percent and non-GAAP earnings per share by 22 percent; we delivered on our fourth-year growth targets; and we advanced and expanded our pipeline. We’re confident 2008 will be another year of strong financial performance and many meaningful clinical data readouts,” says James Mullen, Biogden Idec’s chief executive officer.

More information on the company’s results for the 2007 year can be found at www.biogenidec.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Parata launches PACMED C30 packaging technology

BY Drew Buono

DURHAM, N.C. Parata Systems has launched its new product, the PACMED C30, which is a packaging technology used to extend the safety and convenience of its onePAC packaging system.

onePac is a strip that contains information like patients’ medications, patient names, pill descriptions and time of day to take a dose of the medication. On the strip, up to 19 lines of information can be held. The goal of the strips are to remind patients who take multiple medications when to take what medications and how much of each medication.

The PACMED C30 expands on the technology of the onePAC by combining multiple onePAC strips together for easy access by patients. PACMED C30 is efficient and accurate, generating up to 60 unit-dose or 50 multi-dose packages a minute.

“Adherence is a critical touch point in the circle of pharmacy care, and Parata’s launch of PACMED C30 offers an exciting new way for pharmacies to extend their care by improving patient adherence, safety and convenience,” says Tom Rhoads, executive vice president for customer and market strategies at Parata Systems.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Teva announces availablility of generic Fosamax

BY Drew Buono

NORTH WALES, Pa. Teva has announced the introduction and availability of alendronate sodium tablets.

This is the generic version of the osteoporosis drug Fosamax by Merck. The drug will be available in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg strengths.

“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of sales and marketing. “With the launch of alendronate sodium tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES